Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Anti-CD40 Agonist Monoclonal Antibody ABBV-927	NCIT_C139553	[An agonistic monoclonal antibody directed against the B-cell surface antigen CD40, with potential antineoplastic activity. Upon administration, ABBV-927 binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs), and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells and plays a key role in the activation of the immune system.]
Breast Cancer by AJCC v8 Stage	NCIT_C139532	[A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. It applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)]
Prognostic Stage 0 Breast Cancer AJCC v8	NCIT_C139555	[Stage 0 includes: Tis, N0, M0, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)]
CCR2/CCR5 Antagonist BMS-813160	NCIT_C139550	[An antagonist of both human C-C chemokine receptor types 2 (CCR2; CD192) and 5 (CCR5; CD195), with potential immunomodulating and antineoplastic activities. Upon administration, CCR2/CCR5 antagonist BMS-813160 specifically binds and prevents the activation of both CCR2 and CCR5. This inhibits the activation of CCR2/CCR5-mediated signal transduction pathways and may inhibit inflammatory processes, angiogenesis, tumor cell migration, tumor cell proliferation and invasion. The G-protein coupled chemokine receptors CCR2 and CCR5 are expressed on the surface of monocytes and macrophages, and stimulate their migration and infiltration; they play key roles in inflammation and autoimmune disease. CCR2 and CCR5 are overexpressed in certain cancer cell types, and are also involved in angiogenesis, and in tumor cell migration, proliferation and metastasis.]
Oncolytic HSV-1 rQNestin34.5v.2	NCIT_C139551	[A neuroattenuated, replication-competent, recombinant and genetically-engineered herpes simplex virus type 1 (HSV-1), with potential oncolytic and immunostimulating activities. In rQNestin34.5v.2, the UL39 gene encoding for the viral ribonucleotide reductase large subunit infected cell protein 6 (ICP6) and both endogenous copies of the gamma34.5 gene that encodes for the RL1 neurovirulence protein infected cell protein 34.5 (ICP34.5), which is needed for robust viral growth in an infected cell, are deleted, and one copy of the gamma34.5 gene is reinserted under control of a nestin promoter, which is selectively activated in gliomas. Upon intratumoral administration, oncolytic HSV-1 rQNestin34.5v.2 preferentially infects and replicates within the rapidly dividing, glioma cells, thereby directly lysing tumor cells. The released virus particles, in turn, infect and replicate in neighboring tumor cells, thereby further killing tumor cells. rQNestin34.5v.2 also elicits a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. By inactivating UL39, viral ribonucleotide reductase activity is disrupted, resulting in the inhibition of nucleotide metabolism and viral DNA synthesis in non-dividing, healthy cells but not in dividing cells. Glioma-selective expression of ICP34.5 imparts tumor selectivity by preventing replication in healthy cells.]
CDK7 Inhibitor SY-1365	NCIT_C139552	[A selective inhibitor of cyclin-dependent kinase 7 (CDK7), with potential antineoplastic activity. Upon administration, SY-1365 binds to and inhibits CDK7, thereby inhibiting CDK7-mediated signal transduction pathways. This inhibits cell growth of CDK7-overexpressing tumor cells. CDK7, a serine/threonine kinase, plays a key role in cell proliferation; CDK7 is overexpressed in a variety of tumor cell types.]
Very Little Assistance	NCIT_C139528	[A response indicating that an individual needed very little assistance.]
Used Family or Friend's Smartphone or Tablet	NCIT_C139529	[A response indicating that an individual used a smartphone or tablet belonging to a friend or family member.]
Pre-analytical Handling Problem	NCIT_C139524	[Incorrect pre-analytical handling of patient's sample by the user.]
Ounce	NCIT_C48519	[The traditional unit of mass. The avoirdupois ounce is equal to 1/16 pound, or 28.349 5 grams, or 0.911 457 troy ounce.]
Adverse Event Related to Commutability	NCIT_C139525	[The adverse event occurred because the material being used to calibrate or assess IVD performance did not have similar properties to those of human samples, leading to inappropriate bias and erroneous results. Examples of materials include: reference materials, calibrators, proficiency testing samples.]
Adverse Event Related to Procedure	NCIT_C139526	[The adverse event occurred during the procedure and the device had no influence on event.]
Not Assessed	NCIT_C139527	[Indicates that an assessment was not performed.]
Minim	NCIT_C48514	[A traditional unit of volume used in pharmacies for small quantities of liquids. The US minim is equal to 0.003 760 cubic inch or 61.610 microliters.]
Overheating Problem Identified	NCIT_C139520	[The device was found to become hotter than expected during operation. This applies to devices which are not intended to deliver heat.]
Change in Target Marker/Variant/ Mutant	NCIT_C139521	[Problem due to change in target marker/variant/mutant which is not covered in the labeling.]
Nanogram	NCIT_C48516	[The metric unit of mass equal to one billionth of a gram (10E-9 gram) or one thousandth of a milligram.]
Known Interferent	NCIT_C139522	[Known interferent in the sample identified.]
Nanomole	NCIT_C48517	[A unit of amount of substance equal to 10E-9 mole.]
New or Unknown Interferent	NCIT_C139523	[New or unknown endogenous or exogenous interferent (sample) identified.]